Showing 1 - 6 results of 6 for search 'Simon F Lacey', query time: 5.27s
Refine Results
-
1
CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success by Kristen B. Long, Regina M. Young, Regina M. Young, Alina C. Boesteanu, Megan M. Davis, Megan M. Davis, J. Joseph Melenhorst, J. Joseph Melenhorst, J. Joseph Melenhorst, Simon F. Lacey, Simon F. Lacey, Simon F. Lacey, David A. DeGaramo, Bruce L. Levine, Bruce L. Levine, Joseph A. Fraietta, Joseph A. Fraietta, Joseph A. Fraietta
Published 2018-12-01
Article -
2
Engineered T Cell Therapies from a Drug Development Viewpoint by Fang Chen, Joseph A. Fraietta, Carl H. June, Zhongwei Xu, J. Joseph Melenhorst, Simon F. Lacey
Published 2019-02-01
Article -
3
Establishing a model system for evaluating CAR T cell therapy using dogs with spontaneous diffuse large B cell lymphoma by M. Kazim Panjwani, Matthew J. Atherton, Martha A. MaloneyHuss, Kumudhini P. Haran, Ailian Xiong, Minnal Gupta, Irina Kulikovsaya, Simon F. Lacey, Nicola J. Mason
Published 2020-01-01
Article -
4
PD1 Expression in EGFRvIII-Directed CAR T Cell Infusion Product for Glioblastoma Is Associated with Clinical Response by Oliver Y. Tang, Oliver Y. Tang, Oliver Y. Tang, Oliver Y. Tang, Lifeng Tian, Todd Yoder, Rong Xu, Irina Kulikovskaya, Irina Kulikovskaya, Minnal Gupta, Minnal Gupta, Jan Joseph Melenhorst, Jan Joseph Melenhorst, Jan Joseph Melenhorst, Simon F. Lacey, Simon F. Lacey, Donald M. O’Rourke, Donald M. O’Rourke, Donald M. O’Rourke, Zev A. Binder, Zev A. Binder, Zev A. Binder
Published 2022-05-01
Article -
5
Supraphysiologic control over HIV-1 replication mediated by CD8 T cells expressing a re-engineered CD4-based chimeric antigen receptor. by Rachel S Leibman, Max W Richardson, Christoph T Ellebrecht, Colby R Maldini, Joshua A Glover, Anthony J Secreto, Irina Kulikovskaya, Simon F Lacey, Sarah R Akkina, Yanjie Yi, Farida Shaheen, Jianbin Wang, Keith A Dufendach, Michael C Holmes, Ronald G Collman, Aimee S Payne, James L Riley
Published 2017-10-01
Article -
6
Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma by David L. Bajor, Rosemarie Mick, Matthew J. Riese, Alex C. Huang, Brendan Sullivan, Lee P. Richman, Drew A. Torigian, Sangeeth M. George, Erietta Stelekati, Fang Chen, J. Joseph Melenhorst, Simon F. Lacey, Xiaowei Xu, E. John Wherry, Tara C. Gangadhar, Ravi K. Amaravadi, Lynn M. Schuchter, Robert H. Vonderheide
Published 2018-10-01
Article